Home

Download

Statistics

Landscape

Help

Contact

	Gene summary
	Datasets with differential expression of this gene
	Expression of this gene in the resistant group across all datasets and cell types
	Significant ligand-receptor pairs related to this gene (This gene does not contain this module)
	Known drug resistance mechanisms of this gene (This gene does not contain this module)
	MicroRNAs (miRNAs) regulating this gene
	Motifs and transcription factors (TFs) regulating this gene
	Acts as a transcription factor (This gene does not contain this module)
	Acts as a drug target

Gene: ARPC1B

Summary for ARPC1B

Gene information	Gene symbol	ARPC1B
	Ensembl ID	ENSG00000130429
	Entrez ID	10095
	Gene name	actin related protein 2/3 complex subunit 1B
	Synonyms	ARC41\|p40-ARC\|p41-ARC
	Gene type	protein_coding
	UniProtAcc	NA

Top

Dataset with differentially expressed gene: ARPC1B

Differentially expression genes between the resistant and sensitive groups. A positive avg_log2FC represents significantly high expression in the resistant group, while a negative avg_log2FC represents significantly low expression in the resistant group.

Dataset	Source	Tissue	Cancer type level1	Cancer type level2	Drug type	Regimen	Timepoint	Cell type	avg_log2FC	p_val_adj
GSE138267	CDX	Tumor tissue	Lung cancer	Small cell lung cancer (SCLC)	Chemotherapy	NA	NA	Malignant cells	-0.306731	0.00e+00
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	post	cDCs	0.694996	1.63e-34
GSE169246_PacBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	Mono/Macro	-0.476457	0.00e+00
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	B cells	-0.309598	1.38e-07
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD4+ T cells	-0.337751	7.22e-43
GSE169246_PacTissue	patients	Tumor tissue	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Chemotherapy	paclitaxel	pre	CD8+ T cells	-0.308073	0.00e+00
GSE169246_PacAteBlood	patients	Peripheral blood mononuclear cells	Breast cancer	Advanced triple-negative breast cancer (TNBC)	Immunotherapy	atezolizumab + paclitaxel	pre	cDCs	0.338583	4.50e-09
GSE197268_Axi-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	axi-cel (CAR-T)	post	cDCs	0.294951	1.47e-02
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	CD4+ T cells	-0.432408	8.26e-14
GSE164551	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Immunotherapy	CAR-T	NA	Mono/Macro	-0.465768	2.72e-26
PMID34715028	patients	Tumor tissue	Kidney cancer	Clear cell renal cell carcinoma (ccRCC)	Immunotherapy	nivolumab	post	CD8+ T cells	0.265613	0.00e+00
GSE164237	patients	Peripheral blood mononuclear cells	Melanoma	Advanced stages of melanoma	Immunotherapy	pembrolizumab	pre	CD8+ T cells	-0.326105	0.00e+00
GSE150930	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Mucosa-assisted lymphoid tissue (MALT) lymphoma	Immunotherapy	rituximab + cyclophosphamide + fludarabine	NA	Malignant cells	0.324302	3.87e-17
GSE197268_Tisa-cel	patients	Peripheral blood mononuclear cells	Acute lymphoblastic leukemia	Large B-cell acute lymphoblastic leukemia (B-ALL)	Immunotherapy	tisa-cel (CAR-T)	pre	Mono/Macro	0.306647	0.00e+00
GSE139386	H3122 cell line	Cell line	Lung cancer	EML4-ALK fusion-positive non-small cell lung cancer (NSCLC)	Targeted therapy	ceritinib	NA	Malignant cells	-0.406212	0.00e+00
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	Erythrocytes	0.794576	1.78e-06
GSE162117	patients	Peripheral blood mononuclear cells	Acute myeloid leukemia	Tefractory acute myeloid leukemia (AML)	Targeted therapy	ficlatuzumab	post	CD4+ T cells	0.316086	4.86e-05
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD8+ T cells	0.305626	1.55e-29
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	NK cells	0.946425	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	CD4+ T cells	1.04289	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	B cells	1.39282	1.96e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	post	Malignant cells	0.446702	0.00e+00
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	B cells	-0.841493	8.16e-03
GSE199333	patients	Bone marrow aspirate	Acute myeloid leukemia	Primary FLT3-ITD-mutated acute myeloid leukemia (AML)	Targeted therapy	gilteritinib	pre	CD8+ T cells	-0.531848	2.30e-06
GSE111014	patients	Peripheral blood mononuclear cells	Chronic lymphocytic leukemia	Chronic lymphocytic leukemia (CLL)	Targeted therapy	ibrutinib	post	NK cells	0.442664	1.05e-17
GSE131984_JQ1Pal	SUM159 cell line	Cell line	Breast cancer	Triple-negative breast cancer (TNBC)	Targeted therapy	JQ1 + palbociclib	NA	Malignant cells	0.572531	0.00e+00
GSE104987	MCF7 cell line	Cell line	Breast cancer	ER+ breast cancer	Targeted therapy	KDM5-C70	NA	Malignant cells	-0.498638	0.00e+00
GSE108397	451Lu cell line	Cell line	Melanoma	Melanoma	Targeted therapy	PLX-4720	NA	Malignant cells	-0.570819	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	post	Malignant cells	-0.337454	0.00e+00
GSE161801_IMiD	patients	Bone marrow aspirate	Multiple myeloma	Refractory multiple myeloma (MM)	Targeted therapy	pomalidomide + dexamethasone OR lenalidomide + dexamethasone	pre	Malignant cells	-0.332996	0.00e+00
GSE164897_VemCob	A375 cell line	Cell line	Melanoma	BRAFV600E-mutant melanoma	Targeted therapy	vemurafenib + combimetinib	NA	Malignant cells	-1.45867	0.00e+00
GSE164897_VemTra	A375 cell line	Cell line	Melanoma	B+E2:E57RAFV600E-mutant melanoma	Targeted therapy	vemurafenib + trametinib	NA	Malignant cells	-1.28235	0.00e+00

Top

Expression of ARPC1B in the resistant group across all datasets and cell types

Red dots represent significantly high expression in the resistant group, while blue dots represent significantly low expression in the resistant group. White dots represent that there is no significant difference in the expression of this gene between the resistant and sensitive groups. Blank represents that this cell type is not present in this dataset. (If the image exists, the user can click on it to enlarge it in a new window.)

Top

Significant ligand-receptor pairs related to ARPC1B

This table shows the significant ligand-receptor pairs related to this gene across all datasets, timepoints and conditions. (Complete files can be downloaded from the download section.)

Top

Known drug resistance mechanisms of this gene

This table shows the known drug resistance mechanisms of this gene. Clicking on this gene will link to another database that displays more drug resistance-related information.

Top

MicroRNAs (miRNA) regulating ARPC1B

This table shows the miRNAs with a score of more than 80 regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	miRNA	Score	GeneBank accession
ARPC1B	hsa-miR-634	92.0861	NM_005720
ARPC1B	hsa-miR-3658	91.6543	NM_005720
ARPC1B	hsa-miR-502-5p	86.5883	NM_005720
ARPC1B	hsa-miR-4422	83.258	NM_005720
ARPC1B	hsa-miR-6887-3p	82.6239	NM_005720
ARPC1B	hsa-miR-4672	81.3699	NM_005720

Page: 1

Top

Motifs and transcription factors (TFs) regulating ARPC1B

This table shows the Motifs and transcription factors (TFs) regulating this gene. (Complete files can be downloaded from the download section.)

Gene symbol	motif	TF_highConf
ARPC1B	metacluster_14.28	CLOCK (inferredBy_Orthology).
ARPC1B	taipale_tf_pairs__TEAD4_MAX_RGAATGYNNACGTG_CAP_repr	MAX; TEAD4 (directAnnotation).
ARPC1B	tfdimers__MD00369	ZNF384 (directAnnotation).
ARPC1B	metacluster_170.2	KLF1; KLF10; KLF10; KLF11; KLF11; KLF11; KLF12; KLF12; KLF14; KLF15; KLF17; KLF2; KLF5; KLF7; KLF7; KLF8; MAZ; MAZ; PATZ1; SP1; SP1; SP1; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP2; SP4; SP4; SP5; SP6; SP7; SP8; SP9; ZNF281 (directAnnotation). E2F1; E2F4; KLF10; KLF13; KLF14; KLF17; KLF2; KLF7; SP1; SP1; SP3; SP4; SP5; SP6; SP7 (inferredBy_Orthology).
ARPC1B	transfac_pro__M05628	ZNF735 (directAnnotation).
ARPC1B	hocomoco__KLF13_HUMAN.H11MO.0.D	KLF13 (directAnnotation).
ARPC1B	jaspar__MA0079.5	SP1 (directAnnotation).
ARPC1B	jaspar__MA1483.2	ELF2 (directAnnotation).
ARPC1B	metacluster_33.5	MTF1 (inferredBy_Orthology).
ARPC1B	taipale_tf_pairs__ELF2_NATGCGGAAGTR_HT	ELF2 (directAnnotation).
ARPC1B	jaspar__MA1493.1	HES6 (directAnnotation).
ARPC1B	transfac_pro__M06564	ZNF578 (directAnnotation).
ARPC1B	metacluster_191.2	ELK4; NR2C2; NR2C2; NR2C2; NR2C2 (directAnnotation). GABPA (inferredBy_Orthology).
ARPC1B	metacluster_191.3	EHF; ELF1; ELF1; ELF1; ELF4; ELK1; ELK3; ELK3; ELK4; ELK4; ERF; ETS1; ETS2; ETV3; ETV4; ETV5; FEV; FEV; FLI1; FLI1; GABPA; GABPA; GABPA; GABPA; GABPA; GABPA; SPDEF; ZNF200 (directAnnotation). ELK1; ELK1; ELK3; ELK3; ELK4; ELK4; ETV1; ETV1; ETV4; ETV4; ETV4; ETV5; GABPA; GABPA (inferredBy_Orthology).
ARPC1B	transfac_pro__M00652	NRF1 (directAnnotation).
ARPC1B	taipale_tf_pairs__ATF4_TEF_RNMTGATGCAATN_CAP	ATF4; TEF (directAnnotation).
ARPC1B	hdpi__FLI1	FLI1 (directAnnotation).
ARPC1B	metacluster_22.12	NFE2; NFE2L1 (directAnnotation).
ARPC1B	metacluster_10.17	ARNT (inferredBy_Orthology).
ARPC1B	homer__NVCACGTG_NPAS	NPAS2 (inferredBy_Orthology).
ARPC1B	cisbp__M05832	MAX (directAnnotation).
ARPC1B	transfac_pro__M05605	GATA6 (inferredBy_Orthology).
ARPC1B	kznf__ZNF384_Schmitges2016_RCADE	ZNF384 (directAnnotation).
ARPC1B	hocomoco__MXI1_MOUSE.H11MO.1.A	MXI1 (inferredBy_Orthology).
ARPC1B	taipale_cyt_meth__MLX_NCAYGTGN_eDBD_meth	MLX (directAnnotation).
ARPC1B	tfdimers__MD00567	IKZF2 (directAnnotation).
ARPC1B	transfac_pro__M04844	MAX (directAnnotation).
ARPC1B	dbtfbs__MLX_HepG2_ENCSR125DAD_merged_N1	MLX (directAnnotation).
ARPC1B	transfac_pro__M01116	ARNTL; ARNTL2 (directAnnotation).
ARPC1B	metacluster_10.30	MXI1 (inferredBy_Orthology).
ARPC1B	metacluster_10.46	MAX (inferredBy_Orthology).
ARPC1B	metacluster_14.6	ARNTL; BHLHE40; BHLHE40; CLOCK (directAnnotation). ARNTL; BHLHE41 (inferredBy_Orthology).
ARPC1B	metacluster_2.8	IRF4; IRF5; IRF6; IRF9 (directAnnotation). IRF3; IRF5; IRF5; IRF6 (inferredBy_Orthology).
ARPC1B	taipale_tf_pairs__POU2F1_ELK1_NCCGGATATGCAN_CAP	ELK1; POU2F1 (directAnnotation).
ARPC1B	tfdimers__MD00602	MYB; STAT6 (directAnnotation).
ARPC1B	transfac_pro__M00655	ETV4 (directAnnotation).
ARPC1B	swissregulon__hs__SPI1	SPI1 (directAnnotation).
ARPC1B	tfdimers__MD00527	IRF1; IRF2; IRF3; IRF4; IRF5; IRF6; IRF7; IRF8; ZEB1 (directAnnotation).
ARPC1B	transfac_pro__M02269	FEV (directAnnotation).
ARPC1B	homer__ACAGGATGTGGT_ETS_RUNX	RUNX1 (directAnnotation).
ARPC1B	tfdimers__MD00066	ELF1 (directAnnotation).
ARPC1B	metacluster_2.4	ZIM3; ZIM3; ZIM3; ZIM3 (directAnnotation).
ARPC1B	jaspar__MA1125.1	ZNF384 (directAnnotation).
ARPC1B	metacluster_132.4	MEF2B; MEF2B; MEF2B; MEF2B; MEF2C; MEF2C; MEF2D; MEF2D; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF; SRF (directAnnotation). SRF; SRF; SRF; SRF (inferredBy_Orthology).
ARPC1B	metacluster_22.18	BACH2 (inferredBy_Orthology).
ARPC1B	metacluster_22.39	NFE2L2 (directAnnotation).
ARPC1B	metacluster_130.2	ZNF182; ZNF22; ZNF225; ZNF225; ZNF285; ZNF362; ZNF362; ZNF384; ZNF487; ZNF512; ZNF570; ZNF613 (directAnnotation). ZNF384 (inferredBy_Orthology).
ARPC1B	metacluster_32.28	ZFP28 (directAnnotation).
ARPC1B	taipale_tf_pairs__HOXB2_RFX5_TAATKRNNNNGCAAC_CAP_repr	HOXB2; RFX5 (directAnnotation).
ARPC1B	transfac_pro__M05956	BCL11B (directAnnotation).

Page: 1 2 3

Top

Acts as a transcription factor

This table shows that this differential gene acts as a transcription factor.

Top

Acts as a drug target

This table shows that this differential gene acts as a drug target.

Target name	Drug name	Drug ID	Drug type
ARPC1B	"(2S)-2-(3-bromophenyl)-3-(5-chloro-2-hydroxyphenyl)-1,3-thiazolidin-4-one"	DB08236	small molecule
ARPC1B	"N-[2-(2-methyl-1H-indol-3-yl)ethyl]thiophene-2-carboxamide"	DB08235	small molecule

Page: 1

1	"Sun X, Zhang Y, Li H, Zhou Y, Shi S, Chen Z, He X, Zhang H, Li F, Yin J, Mou M, Wang Y, Qiu Y, Zhu F. DRESIS: the first comprehensive landscape of drug resistance information. Nucleic Acids Res. 2023 Jan 6;51(D1):D1263-D1275. doi: 10.1093/nar/gkac812. PMID: 36243960; PMCID: PMC9825618."
2	"Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037. PMID: 29126136; PMCID: PMC5753335."